The global
therapeutic drug monitoring market is expected to grow at a
CAGR of around 8% during the forecast period. The market growth is
primarily driven by the expansion of personalized medicine, the increasing
prevalence of chronic diseases that need long-term pharmacotherapy, and the
increased focus on patient safety through optimal drug dosing. The market
growth is, however, moderately restrained by the high cost of TDM devices and
reduced access in resource-scarce healthcare environments.
Therapeutic Drug Monitoring (TDM) is a clinical application
aimed at measuring the concentration of certain drugs in the patient’s blood at
specific time intervals. The main goal is to maintain medication in the
therapeutic range—sufficient to be beneficial but not enough to result in
toxicity. TDM is commenced by sample collection (generally blood sample), then
analyzed in the laboratory by using immunoassays or chromatographic techniques.
It is very important for individualizing drug treatment regimens with a narrow
therapeutic window, maximizing drug efficacy and patient safety.
Unlock key findings! Fill out a quick inquiry to access a
sample report
https://meditechinsights.com/therapeutic-drug-monitoring-market/request-sample/
Increasing Prevalence of Chronic Diseases Requiring
Long-Term Medication
One of the key drivers of the widespread adoption of TDM
devices is the global rise in chronic conditions such as cancer, cardiovascular
disease, epilepsy and autoimmune diseases, which require frequent monitoring
and prolonged treatment with drugs that have narrow therapeutic windows,
including immunosuppressants, antiepileptics, and some antibiotics. In these
instances, it is important to sustain drug levels in a specified range—both to
avoid underdosing and overdosing. Since chronic illnesses require ongoing and
accurate dosing over weeks or months, physicians are now relying more on TDM to
individualize treatment regimens and improve patient safety. Additionally, the
rising geriatric population and the common use of complex drug regimens (mainly
in oncology and transplant medicine) have further expanded the clinical
relevance of TDM. This emerging medical need is directly correlating with
increased demand for monitoring devices and services by hospitals and
diagnostic laboratories.
Integration of Microsampling Techniques
in Therapeutic Drug Monitoring
One of the most significant innovations augmenting TDM is
the creation of microsampling technologies, including volumetric absorptive
microsampling (VAMS) and dried blood spot (DBS) testing. These technologies
enable the collection of very small volumes of blood—often a few
microliters—via minimally invasive procedures like finger pricks. In contrast
to standard venipuncture, microsampling does not involve skilled phlebotomists
or large volumes of blood, so it is less invasive for patients and more convenient
for outpatient or home settings. Microsampling is particularly valuable with
pediatric, geriatric, and rural populations, where standard sampling proves
difficult. The less complicated logistics also allow for samples to be taken in
non-clinical settings and sent by mail to central labs without requiring cold
chain shipping. As a result, microsampling has enhanced the patient compliance
and feasibility considerably in standard TDM programs, thus facilitating
broader use and increased monitoring in clinical practice.
Competitive Landscape Analysis
The global therapeutic drug monitoring market is marked by
the presence of established and emerging market players such as Abbott;
ALPCO; Danaher Corporation; Bio-Rad Laboratories, Inc; Thermo Fisher Scientific
Inc.; F.Hoffmann-La Roche Ltd.; Randox laboratories Ltd; Siemens
Healthineers AG.; biomérieux, Inc. and Chromsystems
Instruments & Chemicals GmbH among others. Some of the
key strategies adopted by market players include new product development,
strategic partnerships and collaborations, and geographic expansion.
Get exclusive insights - download your sample report
today
https://meditechinsights.com/therapeutic-drug-monitoring-market/request-sample/
Market Segmentation
This report by Medi-Tech Insights provides the size of
the global therapeutic drug monitoring market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on product, drug class, therapeutic area and end-user.
- Market
Size & Forecast (2023-2030), By Product, USD Million
- Equipment
- Immunoassay
Analyzers
- Clinical
Chemistry Analyzers
- Chromatography
& MS Detectors
- Consumables
- Market
Size & Forecast (2023-2030), By Drug Class, USD Million
- Antiepileptic
Drugs
- Immunosuppressants
- Antiarrhythmic
Drugs
- Others
- Market
Size & Forecast (2023-2030), By Therapeutic Area, USD Million
- Cancer
- Cardiovascular
Diseases
- Autoimmune
Diseases
- Others
- Market
Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals
- Diagnostic
Centers
- Others
- Market
Size & Forecast (2023-2030), By Region, USD Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research combined
with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply
side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment